Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OliNAC Trial: Neoadjuvant PAV Chemotherapy in Oligodendroglioma
jRCT1031250745Phase 2Recruiting
- Start
- Feb 2026
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimustine, procarbazine and vincristine in Oligodendroglioma (OG), sponsored by None. Primary endpoint: 5-year progression-free survival (5y-PFS). Started Feb 2026; status: recruiting.
02
Drugs
nimustineprocarbazinevincristine
03
Conditions
Oligodendroglioma (OG)
Beyond the preview
Go deeper on jRCT1031250745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250745.